SciELO - Scientific Electronic Library Online

 
vol.44 número3Prevalencia de diabetes mellitus tipo 2 y su tratamiento farmacológico en personas institucionalizadas en centros residencialesBiosimilares de anticuerpos monoclonales en enfermedades inflamatorias y cáncer: situación actual, retos y oportunidades índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343

Resumen

DIAZ-ACEDO, Rocío; ARTACHO-CRIADO, Silvia; GALVAN-BANQUERI, Mercedes  y  LOPEZ-ALVAREZ, Pilar. Real world study of pertuzumab-trastuzumab-chemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer. Farm Hosp. [online]. 2020, vol.44, n.3, pp.96-99.  Epub 19-Oct-2020. ISSN 2171-8695.  http://dx.doi.org/10.7399/fh.11376.

Objective:

The primary objective of the study is to compare the effectiveness of trastuzumab-chemotherapy with and without pertuzumab. As a secondary objective, we seek to evaluate the cardiac safety of the treatment.

Method:

Retrospective observational study including all patients treated with either pertuzumab-trastuzumab-chemotherapy (n = 10) or trastuzumab-chemotherapy (n = 13) (January 2015-December 2018) in a specialty hospital, which met the criteria established by the Commission Central for the Optimization and Harmonization of the pharmacotherapy of the Andalusian Health Service for the use of pertuzumab in neoadjuvance: HER2 positive tumor, negative hormonal receptors, with high risk of relapse (tumor > 2 cm or lymph node involvement). To assess effectiveness, the complete pathological response was used. For cardiac safety, the decrease in left ventricular ejection fraction greater than 10% was employed.

Results:

Complete pathological response was superior in the pertuzumab group (70.0% vs. 30.8%). Cardiac safety was similar in both.

Conclusions:

For patients with HER2 positive tumors and negative hormonal receptors with high risk criteria that receive pertuzumab, the complete pathological response is superior, with no increase in cardiac toxicity.

Palabras clave : Pertuzumab; Trastuzumab; Pathological complete response; Breast cancer; Neoadjuvance.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )